Faster global financial news!
Merck
-
Moderna's shares surged on Monday ahead of the release of Phase III data for its mRNA cancer vaccine next month.
Moderna's stock surged on Monday after the biotechnology company confirmed it would release highly anticipated Phase III data for its experimental mRNA cancer vaccine next month. The vaccine is being
-
Merck stock surged 84% in the past year, outperforming S&P 500, but analysts question if its future beyond Keytruda is priced in too soon given its low profitability.
Merck's shares have climbed 84% over the last twelve months, significantly outpacing the S&P 500's 19.1% gain and making it a top performer among peers. However, its operational metrics, including a 4
-
Merck & Co. (MRK) stock is nearing its valuation limit due to slowing growth in its core oncology products, analysis indicates.
Merck & Co.'s stock price has surged 85.5% over the past 12 months, with its current price-to-sales (P/S) ratio reaching 5.7x, close to its decade-high of 5.9x. Analysis suggests that its core oncolog
-
Moderna's stock doubles on promising cancer-vaccine results
The vaccine candidate, developed with Merck, is an mRNA therapy paired with the cancer drug Keytruda. It helped melanoma patients live longer in a late-stage trial, marking the first Phase 3 data for
-
Moderna's shares surged on Monday ahead of the release of Phase III data for its mRNA cancer vaccine next month.
Moderna's stock surged on Monday after the biotechnology company confirmed it would release highly anticipated Phase III data for its experimental mRNA cancer vaccine next month. The vaccine is being
-
Merck stock surged 84% in the past year, outperforming S&P 500, but analysts question if its future beyond Keytruda is priced in too soon given its low profitability.
Merck's shares have climbed 84% over the last twelve months, significantly outpacing the S&P 500's 19.1% gain and making it a top performer among peers. However, its operational metrics, including a 4
-
Merck & Co. (MRK) stock is nearing its valuation limit due to slowing growth in its core oncology products, analysis indicates.
Merck & Co.'s stock price has surged 85.5% over the past 12 months, with its current price-to-sales (P/S) ratio reaching 5.7x, close to its decade-high of 5.9x. Analysis suggests that its core oncolog
-
Moderna's stock doubles on promising cancer-vaccine results
The vaccine candidate, developed with Merck, is an mRNA therapy paired with the cancer drug Keytruda. It helped melanoma patients live longer in a late-stage trial, marking the first Phase 3 data for
- No data
Merck
24H Trending
-
1
Regulatory Landscape and Exchange Policies for Virtual Currencies in Mainland China
-
2
Cerebras's pre-market stock rose 6% after OpenAI CEO Altman called Cerebras a "close partner."
-
3
Bitcoin (BTC): Latest Updates and Market Analysis of Digital Gold
-
4
Litecoin's price has recently surged: Can ETF applications and halving expectations sustain its rally?
-
5
Cryptocurrency Information Platforms and Software Download Guide: Secure Access to Industry News and Trading Tools
-
6
Multiple U.S. states will vote on wealth taxes in November, with California potentially imposing a 5% net worth tax on billionaires.
-
7
Ethereum: Market Impact, Technological Advancements, and Future Outlook
-
8
Decoding the Connection Mechanism of Bitcoin Private Keys, Public Keys, and Wallet Addresses
-
9
STEEM Coin Analysis: The Current Status and Development Challenges of a Decentralized Social Blockchain
-
10
SOL Rebounds Strongly: Can Solana Reach New All-Time Highs?
Markets Today
Recommended Reading
Hot Topics
Svmuu focuses on blockchain industry trends and cutting-edge cryptocurrency news, while also covering real-time market data and in-depth analysis of the Hong Kong, U.S., and foreign exchange markets. Here, you can not only access professional 24/7 news updates and accurate market data, but also utilize practical investment tools to help you capitalize on opportunities in both digital assets and traditional financial markets. Whether you are a blockchain enthusiast or an investor in Hong Kong, U.S., or foreign exchange markets, we provide efficient and timely information services to empower your investment decisions.
- User Agreement
- Privacy Policy
- Contact Us
- Business Partnerships
- Disclaimer
- Content Statement
- About Us
- Sitemap
Coming Soon!
